



## COMPANY OVERVIEW

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.

## RECENT NEWS

### **Anixa Biosciences to Hold Conference Call to Discuss Outlook for 2019**

Jan 16 2019, 7:30 AM EST

### **Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test**

Dec 19 2018, 7:00 AM EST

### **Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference**

Dec 3 2018, 7:00 AM EST

## STOCK OVERVIEW

Symbol	ANIX
Exchange	Nasdaq
Market Cap	82.19m
Last Price	\$4.26
52-Week Range	\$2.62 - \$6.86

01/18/2019 04:00 PM EST

## INVESTOR RELATIONS

Mike Catelani  
Chief Operating Officer & Chief  
Financial Officer  
T: 408-708-9808

## MANAGEMENT TEAM

### **Dr. Amit Kumar, Ph.D**

Chairman, President & Chief Executive Officer

### **Michael Catelani**

Chief Operating Officer and Chief Financial Officer

### **John Roop**

Senior Vice President of Engineering

### **Anthony Campisi**

Vice President of Engineering

---

## ANIXA BIOSCIENCES, INC.

3150 Almaden Expressway  
Suite 250  
San Jose, CA 95118  
US

---

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.